Published by mark itwired
Posted on September 6, 2021
The global whole genome amplification market is estimated at around US$ 5.08 Bn by the end of 2031, as indicated by a recent report released by Future Market Insights. The global market for whole genome amplification will possibly expand at a CAGR of 7.9% during the forecast period, 2021-2031
A US-based team of researchers has recently developed a microfluidic device for isolating a genomic DNA, which is to be purified later. This DNA is sourced from individual cells and the device physically catches single cells using a micropillar array.
It also captures chromosomal DNA of these single cells post-extraction, which is later immobilized in the micropillar array so as to enable the process of isothermal amplification. The entire methodology is referred to as ‘on-chip cell capture and DNA extraction’.
As conventional single cell WGA is often prone to amplification biases, which may hold a significant influence on the accuracy of the data of single cell sequencing.
This drawback is foreseen to be overcome with the introduction of single cell on-chip WGA, resulting in reduced biases regarding amplification, offering an improved coverage of the genome. The team has used individual cancer cell genomes (human), sourced from the HeLa Cell Line.
WGA has been a crucial procedure that helps in DNA analysis from limited quantities of genomic DNA. The ease provided by various WGA kits available for the entire process has been driving the market over the years.
Increasing research activities will remain the key factor pushing the growth of whole genome amplification market over the next decade. Adoption of this process is expected to witness robust growth, predominantly among research institutes, hospitals, diagnostic centers, and forensic labs, as it offers an improved and advanced means of genome amplification and sequencing.
To increase the revenue share, molecular testing companies are focusing more on the development of advanced devices and kits such as WGA kits and complete WGA kits with advanced capabilities
Get Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1873
The global whole genome amplification market is estimated at around US$ 5.08 Bn by the end of 2031, as indicated by a recent report released by Future Market Insights. The global market for whole genome amplification will possibly expand at a CAGR of 7.9% during the forecast period, 2021-2031.
Introduction of massively parallel single-cell genome sequencing is anticipated to offer a new dimension to the understanding of genetic diversities in complex biological systems.
Single cell WGA is a method used to examine the sequence information with the optimized next generation sequencing technologies, only from a single cell. This method is considered to be a powerful tool that helps to understand the ins and outs of genetics by bringing the entire genome structure to a cellular level.
Since this method offers a high-resolution view of the genomic sample, its adoption will continue to be on the rise in diverse biological fields such as microbiology, immunology, neurobiology, cancer research, and tissue mosaicism.
Single cell WGA also plays a crucial role in conveying new applications to the market, eventually pushing the market growth further through 2031.
As a move towards better results and implementation of advanced technology, novel techniques are being introduced in the new WGA products.
The TruePrime Single Cell WGA Kit (Expedeon Ltd.), utilizes a unique and reliable method to achieve accurate genome amplification from single cells. TruePrime technology uses a revolutionary novel multiple displacement amplification (MDA) method based on the combination of the recently discovered DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 DNA polymerase to amplify uniformly total genomic DNA either a single or a few cells.
Similarly MALBAC Multiple annealing and Looping Based Amplification Cycles) technology and PicoPLEX® WGA kit (Rubicon Genomics), with patented technology are the other options that have been unveiled as the latest and advanced technologies which are more efficient and optimized in the results and analysis outcomes.
Increasing prevalence of infectious diseases and oncology disorders has increased the demand for WGA devices and kits, fueling the growth of companies dealing in WGA kits.
Despite the market having several large players as well as multiple smaller companies, there are limited companies that have a complete focus on being a provider of life science products and reagents.
Vendors have different specializations and product offerings, with most of the large companies combining research products and reagents with equipment, in-vitro diagnostics tools etc.
However, the companies that have a sole focus on this market can have better growth prospects in the coming future.
They can ensure better quality of products, customer loyalty and an established distribution network that can cater to product availability around the globe.
The key players of the market, including GE Healthcare, Sygnis AG, Illumina, Inc., Merck KGaA, Thermo Fisher Scientific Inc., and Active Motif are inclined more towards strategic acquisitions and mergers.
They are also looking for distribution and collaboration agreements to help improve their product reach. It will also help them serve end users better, with diagnostic consulting and good laboratory practices. High price point may remain a major challenge for companies.
Any Questions About Report, Speak to Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-1873
The market valuation of whole genome amplification experienced a year-o-year growth of 8% from 2020 to 2021. The whole genome amplification market is worth around US$ 2378.3Mn in 2021
Between 2016 and 2020, the whole genome amplification sales surged at a 5.7% CAGR. The market’s valuation stood at US$ 2202.3Mn in 2020.
Increasing advancement in the field of DNA sequencing and genome amplification, the sales of whole genome amplification kit will increase by 2.13 times, reaching a market valuation of US$ 5087.4 Mn by the end of 2031.
U.S., U.K., and Germany are the leading manufacturers for whole genome amplification kits owing to increasing government and private funding for healthcare development and presence of leading market players in the country.
Demand registered in North America will continue rising, backed increasing sales in the U.S. and Canada, the North America market will account for 38% of global demand of whole genome amplification kits.
GE Healthcare, Merck KGaA, and Thermo Fisher Scientific Inc., and Active Motif are the key exporters operating in the whole genome amplification market.
The post Whole Genome Amplification Market Competitive Analysis, Growth Prospects, Segmentation & Forecast 2031 first appeared on Market Research Blog.
The global whole genome amplification market is estimated at around US$ 5.08 Bn by the end of 2031, as indicated by a recent report released by Future Market Insights. The global market for whole genome amplification will possibly expand at a CAGR of 7.9% during the forecast period, 2021-2031
A US-based team of researchers has recently developed a microfluidic device for isolating a genomic DNA, which is to be purified later. This DNA is sourced from individual cells and the device physically catches single cells using a micropillar array.
It also captures chromosomal DNA of these single cells post-extraction, which is later immobilized in the micropillar array so as to enable the process of isothermal amplification. The entire methodology is referred to as ‘on-chip cell capture and DNA extraction’.
As conventional single cell WGA is often prone to amplification biases, which may hold a significant influence on the accuracy of the data of single cell sequencing.
This drawback is foreseen to be overcome with the introduction of single cell on-chip WGA, resulting in reduced biases regarding amplification, offering an improved coverage of the genome. The team has used individual cancer cell genomes (human), sourced from the HeLa Cell Line.
WGA has been a crucial procedure that helps in DNA analysis from limited quantities of genomic DNA. The ease provided by various WGA kits available for the entire process has been driving the market over the years.
Increasing research activities will remain the key factor pushing the growth of whole genome amplification market over the next decade. Adoption of this process is expected to witness robust growth, predominantly among research institutes, hospitals, diagnostic centers, and forensic labs, as it offers an improved and advanced means of genome amplification and sequencing.
To increase the revenue share, molecular testing companies are focusing more on the development of advanced devices and kits such as WGA kits and complete WGA kits with advanced capabilities
Get Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1873
The global whole genome amplification market is estimated at around US$ 5.08 Bn by the end of 2031, as indicated by a recent report released by Future Market Insights. The global market for whole genome amplification will possibly expand at a CAGR of 7.9% during the forecast period, 2021-2031.
Introduction of massively parallel single-cell genome sequencing is anticipated to offer a new dimension to the understanding of genetic diversities in complex biological systems.
Single cell WGA is a method used to examine the sequence information with the optimized next generation sequencing technologies, only from a single cell. This method is considered to be a powerful tool that helps to understand the ins and outs of genetics by bringing the entire genome structure to a cellular level.
Since this method offers a high-resolution view of the genomic sample, its adoption will continue to be on the rise in diverse biological fields such as microbiology, immunology, neurobiology, cancer research, and tissue mosaicism.
Single cell WGA also plays a crucial role in conveying new applications to the market, eventually pushing the market growth further through 2031.
As a move towards better results and implementation of advanced technology, novel techniques are being introduced in the new WGA products.
The TruePrime Single Cell WGA Kit (Expedeon Ltd.), utilizes a unique and reliable method to achieve accurate genome amplification from single cells. TruePrime technology uses a revolutionary novel multiple displacement amplification (MDA) method based on the combination of the recently discovered DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 DNA polymerase to amplify uniformly total genomic DNA either a single or a few cells.
Similarly MALBAC Multiple annealing and Looping Based Amplification Cycles) technology and PicoPLEX® WGA kit (Rubicon Genomics), with patented technology are the other options that have been unveiled as the latest and advanced technologies which are more efficient and optimized in the results and analysis outcomes.
Increasing prevalence of infectious diseases and oncology disorders has increased the demand for WGA devices and kits, fueling the growth of companies dealing in WGA kits.
Despite the market having several large players as well as multiple smaller companies, there are limited companies that have a complete focus on being a provider of life science products and reagents.
Vendors have different specializations and product offerings, with most of the large companies combining research products and reagents with equipment, in-vitro diagnostics tools etc.
However, the companies that have a sole focus on this market can have better growth prospects in the coming future.
They can ensure better quality of products, customer loyalty and an established distribution network that can cater to product availability around the globe.
The key players of the market, including GE Healthcare, Sygnis AG, Illumina, Inc., Merck KGaA, Thermo Fisher Scientific Inc., and Active Motif are inclined more towards strategic acquisitions and mergers.
They are also looking for distribution and collaboration agreements to help improve their product reach. It will also help them serve end users better, with diagnostic consulting and good laboratory practices. High price point may remain a major challenge for companies.
Any Questions About Report, Speak to Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-1873
The market valuation of whole genome amplification experienced a year-o-year growth of 8% from 2020 to 2021. The whole genome amplification market is worth around US$ 2378.3Mn in 2021
Between 2016 and 2020, the whole genome amplification sales surged at a 5.7% CAGR. The market’s valuation stood at US$ 2202.3Mn in 2020.
Increasing advancement in the field of DNA sequencing and genome amplification, the sales of whole genome amplification kit will increase by 2.13 times, reaching a market valuation of US$ 5087.4 Mn by the end of 2031.
U.S., U.K., and Germany are the leading manufacturers for whole genome amplification kits owing to increasing government and private funding for healthcare development and presence of leading market players in the country.
Demand registered in North America will continue rising, backed increasing sales in the U.S. and Canada, the North America market will account for 38% of global demand of whole genome amplification kits.
GE Healthcare, Merck KGaA, and Thermo Fisher Scientific Inc., and Active Motif are the key exporters operating in the whole genome amplification market.
The post Whole Genome Amplification Market Competitive Analysis, Growth Prospects, Segmentation & Forecast 2031 first appeared on Market Research Blog.
Explore more articles in the Research Reports category
